QUANTITATIVE IMMUNOFLUORESCENT DETECTION OF RRM1 PROTEIN IN OVARIAN CANCER TISSUE BY FLOW CYTOMETRY
https://doi.org/10.17650/1726-9784-2016-15-3-87-89
Abstract
Objective of the research was determination level of RRM1 expression in ovarian cancer tissue. Materials and methods. To avoid disadvantages of those evaluations, the present study of the RRM1 expression level in ovarian cancer tissue determination was held using strictly quantitative immunofluorescence flow cytometry-associated method developed by the authors. Results. RRM1 expression was detected in 100 % of samples of ovarian serous adenocarcinoma, with significant differences in the indicator level in variable patients. The high level of RRM1 (≥ 40 % of cells expressing the marker) was detected in 65 % of the tumor samples studied, low (< 40 %) - in 35 % of cases. Data on the lower expression of RRM1 in one-third of the test samples from primary serous ovarian cancer corresponds with clinical observations of gemcitabine monotherapy efficiency in 25-30 % of patients. Conclusion. The authors believe that a strictly quantitative determination of the marker level in tumor tissue can help to overcome the ambiguity of RRM1 clinical significance estimation in gemcitabine treatment effectiveness prediction.
About the Authors
S. A. Kalyuzhny
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
E. A. Dudko
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
V. T. Zarkua
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
E. A. Bogush
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
V. Yu. Kirsanov
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
S. D. Kolomiytsev
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
N. O. Vichlyantseva
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
A. S. Tyulandina
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
T. A. Bogush
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Russian Federation
Russian Federation
References
1. Тюляндина А.С. Лекарственное лечение рака яичников. Практическая онкология 2014; 15(4): 168-75.
2. Jordheim L.P., Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 2007; 1776(2): 138-59. PMID: 17881132.
3. Besse B., Olaussen K.A., Soria J.C. ERCC1 and RRM1: ready for prime time? J Clin Oncol 2013; 31(8): 1050-60. DOI: 10.1200/JCO.2012.43.0900. PMID: 23401439.
4. Jordheim L.P., Sève P., Trédan O., Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011; 12(7): 693-702. DOI: 10.1016/S1470-2045(10)70244-8. PMID: 21163702.
5. Edwards S.J., Barton S., Thurgar E. Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2015; 19(7): 1-11. DOI: 10.3310/hta19070. PMID: 25626481.
Review
For citations:
Kalyuzhny S.A., Dudko E.A., Zarkua V.T., Bogush E.A., Kirsanov V.Yu., Kolomiytsev S.D., Vichlyantseva N.O., Tyulandina A.S., Bogush T.A. QUANTITATIVE IMMUNOFLUORESCENT DETECTION OF RRM1 PROTEIN IN OVARIAN CANCER TISSUE BY FLOW CYTOMETRY. Russian Journal of Biotherapy. 2016;15(3):87-89. (In Russ.) https://doi.org/10.17650/1726-9784-2016-15-3-87-89
Views:
371
Email this article 
